Background Tranexamic acid (TXA) reduces surgical bleeding and reduces death from
bleeding after trauma and childbirth. However, its effects on thrombotic events and seizures …

Objective To assess the effect of tranexamic acid on blood transfusion, thromboembolic
events, and mortality in surgical patients. Design Systematic review and meta-analysis. Data …

Tranexamic acid, a synthetic derivative of the amino acid lysine, is an antifibrinolytic agent
that acts by binding to plasminogen and blocking the interaction of plasmin (ogen) with …

The aims of severe perioperative bleeding management are three-fold. First, preoperative
identification by anamesis and laboratory testing of those patients for whom the …

Background—Since the 1980s, antifibrinolytic therapies have assisted surgical teams in
reducing the amount of blood loss. To date, however, serious questions remain regarding …

Background Tranexamic acid (TA) reduces blood loss and blood transfusion during heart
surgery with cardiopulmonary bypass (CPB). TA dosing has been empiric because only …

Background It is unclear whether high-dose regimens of tranexamic acid in cardiac surgery
(total dose, 80 to 100 mg/kg) confer a clinical advantage over low-dose regimens (total dose …

Patients undergoing cardiac surgery with cardiopulmonary bypass are at risk for excessive
microvascular bleeding, which often leads to transfusion of allogeneic blood and blood …

Skilful surgery combined with blood-saving methods and careful management of blood
coagulation will all help reduce unnecessary blood loss and transfusion requirements …

BACKGROUND: The acute coagulopathy of trauma has been identified as a critical
determinant of outcomes. Antifibrinolytic agents have recently been demonstrated to …